Literature DB >> 17083026

Risk of cardiovascular disease in a cohort of HIV-infected adults: a study using carotid intima-media thickness and coronary artery calcium score.

Alexandra Mangili1, Jul Gerrior, Alice M Tang, Daniel H O'Leary, Joseph K Polak, Ernst J Schaefer, Sherwood L Gorbach, Christine A Wanke.   

Abstract

BACKGROUND: There is concern that human immunodeficiency virus (HIV) infection and the use of highly active antiretroviral therapy lead to accelerated atherosclerosis and increased risk of cardiovascular disease. We measured 2 surrogate markers of subclinical atherosclerosis, carotid intima-media thickness (c-IMT) and coronary artery calcium (CAC) scores, in HIV-infected adults.
METHODS: A cross-sectional analysis of 242 men and 85 women with HIV infection was used. Carotid ultrasonography and coronary computed tomography were performed, and their associations with cardiovascular risk factors were examined.
RESULTS: Among men, the mean (+/- standard deviation [SD]) common c-IMT was 0.62+/-0.2 mm, the mean (+/-SD) internal c-IMT was 0.76+/-0.5 mm, and 136 patients (56.1%) had detectable CAC. Among women, the mean (+/-SD) common c-IMT was 0.59+/-0.2 mm, the mean (+/-SD) internal c-IMT was 0.66+/-0.4 mm, and 40 patients (47.1%) had detectable CAC. Neither the c-IMT nor the CAC score differed by antiretroviral therapy class or individual medications for either sex. For men, age and waist circumference independently predicted common c-IMT; age, systolic blood pressure, and high-sensitivity C-reactive protein level independently predicted internal c-IMT; and age, apolipoprotein B level, and high-sensitivity C-reactive protein level independently predicted CAC score. For women, age and body mass index independently predicted common c-IMT; age independently predicted internal c-IMT; and age and glucose level independently predicted CAC score.
CONCLUSIONS: Our participants had more abnormal surrogate markers than expected at a relatively young age, but those were not associated with use of highly active antiretroviral therapy or protease inhibitors. At present, the positive associations were primarily with traditional and novel cardiovascular risk factors. Some HIV-specific (not treatment-specific) factors were observed; they may become more evident with prolonged HIV infection and treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17083026     DOI: 10.1086/509575

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  42 in total

1.  Carotid intima-media thickness among human immunodeficiency virus-infected patients without coronary calcium.

Authors:  Priscilla Y Hsue; Karen Ordovas; Theodore Lee; Gautham Reddy; Michael Gotway; Amanda Schnell; Jennifer E Ho; Van Selby; Erin Madden; Jeffrey N Martin; Steven G Deeks; Peter Ganz; David D Waters
Journal:  Am J Cardiol       Date:  2011-12-09       Impact factor: 2.778

2.  Risk stratification and prognosis of human immunodeficiency virus-infected patients with known or suspected coronary artery disease referred for stress echocardiography.

Authors:  Omar Wever Pinzon; Jorge Silva Enciso; Jorge Romero; Harikrishna Makani; Jose Fefer; Vani Gandhi; Sripal Bangalore; Farooq A Chaudhry
Journal:  Circ Cardiovasc Imaging       Date:  2011-07-12       Impact factor: 7.792

3.  Coronary and peripheral endothelial function in HIV patients studied with positron emission tomography and flow-mediated dilation: relation to hypercholesterolemia.

Authors:  Anne-Mette Lebech; Ulrik Sloth Kristoffersen; Niels Wiinberg; Kristian Kofoed; Ove Andersen; Birger Hesse; Claus Leth Petersen; Jan Gerstoft; Andreas Kjaer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-07-26       Impact factor: 9.236

4.  State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary.

Authors:  Steven K Grinspoon; Carl Grunfeld; Donald P Kotler; Judith S Currier; Jens D Lundgren; Michael P Dubé; Steven E Lipshultz; Priscilla Y Hsue; Kathleen Squires; Morris Schambelan; Peter W F Wilson; Kevin E Yarasheski; Colleen M Hadigan; James H Stein; Robert H Eckel
Journal:  Circulation       Date:  2008-06-19       Impact factor: 29.690

Review 5.  Noninvasive assessment of HIV-related coronary artery disease.

Authors:  Louis H Miller; John T Coppola
Journal:  Curr HIV/AIDS Rep       Date:  2011-06       Impact factor: 5.071

6.  Associations of antiretroviral drug use and HIV-specific risk factors with carotid intima-media thickness.

Authors:  Joseph A C Delaney; Rebecca Scherzer; Mary L Biggs; Michael G Shliplak; Joseph F Polak; Judith S Currier; Richard A Kronmal; Christine Wanke; Peter Bacchetti; Daniel O'leary; Phyllis C Tien; Carl Grunfeld
Journal:  AIDS       Date:  2010-09-10       Impact factor: 4.177

7.  HIV and coronary artery calcium score: comparison of the Hawaii Aging with HIV Cardiovascular Study and Multi-Ethnic Study of Atherosclerosis (MESA) cohorts.

Authors:  Dominic Chow; Rebekah Young; Nicole Valcour; Richard A Kronmal; Corey J Lum; Nisha I Parikh; Russell P Tracy; Matthew Budoff; Cecilia M Shikuma
Journal:  HIV Clin Trials       Date:  2015-06-03

8.  Subclinical coronary atherosclerosis, HIV infection and antiretroviral therapy: Multicenter AIDS Cohort Study.

Authors:  Lawrence A Kingsley; Juliana Cuervo-Rojas; Alvaro Muñoz; Frank J Palella; Wendy Post; Mallory D Witt; Matthew Budoff; Lewis Kuller
Journal:  AIDS       Date:  2008-08-20       Impact factor: 4.177

9.  Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men.

Authors:  Robert C Kaplan; Lawrence A Kingsley; Stephen J Gange; Lorie Benning; Lisa P Jacobson; Jason Lazar; Kathryn Anastos; Phyllis C Tien; A Richey Sharrett; Howard N Hodis
Journal:  AIDS       Date:  2008-08-20       Impact factor: 4.177

10.  Comparison of brachial and carotid artery ultrasound for assessing extent of subclinical atherosclerosis in HIV: a prospective cohort study.

Authors:  Adefowope Odueyungbo; Marek Smieja; Lehana Thabane; Fiona Smaill; Kevin Gough; John Gill; Todd Anderson; Dawn Elston; Sandy Smith; Joseph Beyene; Eva Lonn
Journal:  AIDS Res Ther       Date:  2009-06-11       Impact factor: 2.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.